Kornimate/medical-research-clean huggingface dataset:
a quality of life study using insulin potentiation targeted lowdose (iptld) chemotherapy and nutrition therapy in the treatment of cancer

Conditions: Cancer

Summary: the iptld qol broad study.

a quality of life study using insulin potentiation targeted lowdose (iptld) chemotherapy and nutrition therapy in the treatment of cancer.

Eligibility criteria:
inclusion criteria: * diagnosis of cancer, * age older than 18 years, * requesting iptld and nutrition therapy exclusion criteria: * diagnosis other than cancer, * age younger than 18 years, * requesting conventional chemotherapy

Keywords: cancer insulin potentiation low dose chemotherapy ipt iptld nutrition therapy
cifn and ifn γ-1b with or without ribavirin for treatment of chronic hepatitis c (nonresponders)

Conditions: Chronic Hepatitis C

Summary: to evaluate the safety and tolerability of two different doses of consensus interferon-alpha and interferon gamma-1b with or without ribavirin in patients with chronic hepatitis c who are non-responders to peg-ifn-a 2a or peg-ifn-a 2b plus ribavirin.


Eligibility criteria:
inclusion criteria: 1. signed, written, informed consent from the patient or legal representative before any study-specific procedures are performed 2. male or female 18 years of age or older 3. chronic hepatitis c infection based on history of positive serum anti-hcv antibody and/or hcv rna 4. patients must have documented failure to respond to past treatment with peg-intron or pegasys plus rbv. 5. liver biopsy within 3 years of screening documenting chronic liver disease consistent with chronic hepatitis c exclusion criteria: 1. patients with any history of decompensated liver disease including but not restricted to portal hypertension as manifested by gastroesophageal varices, variceal bleeding, ascites, or encephalopathy 2. specific laboratory abnormalities at screening 3. patients who were hcv rna negative during prior pegylated interferon plus ribavirin treatment, but who relapsed during follow-up 4. recent depression or psychiatric disorders 5. known hiv infection or positive hiv antibody test at screening 6. chronic hepatitis b infection or positive hepatitis b surface antigen (hbsag) at screening 7. unstable or uncontrolled thyroid disease 8. presence or history of non-hcv chronic liver disease 9. history of unstable or deteriorating cardiovascular or cerebrovascular disease within 6 months prior to screening 10. current or history of neurologic disorder within a specified time frame 11. a disease known to cause significant alteration in immunologic function including hematological malignancy, sarcoidosis or autoimmune disorder (e.g. rheumatoid arthritis, systemic lupus erythematosis, leukemia, lymphoma, autoimmune thyroid disease, scleroderma, psoriasis, inflammatory bowel disease, multiple sclerosis etc.) 12. history of major organ transplantation (i.e., liver, kidney, lung, or heart) with an existing functional graft, including bone marrow transplant or stem cell transplant 13. concurrent therapy with immunosuppressive drugs or cytotoxic agents such as cyclosporine, azathioprine, chronic systemic corticosteroids, or chemotherapeutic agent(s) (e.g., cyclophosphamide, methotrexate, or cancer chemotherapy) or radiation therapy 14. pregnant or lactating women 15. liver biopsy within the past three years documenting cirrhosis

Keywords: chronic hepatitis c liver pegylated interferon alpha gamma ribavirin combination nonresponder pegasys pegintron
characterization of high density lipoprotein (hdl) in type 2 diabetes (t2d) after fenofibrate or niacin treatment

Conditions: Type 2 Diabetes Mellitus; Dyslipidemia

Summary: the structural and functional alterations of high density lipoproteins (hdl) levels in type 2 diabetes (t2d) patients linked to hypertriglyceridemia, hyperglycemia, insulin resistance, inflammation and oxidation, play a major role in the increased macrovascular risk in these patients. an impaired function of the adipose tissue (at) in t2d contributes to low hdl concentrations. objectives: 1) quantitative and qualitative characterisation of hdl subclasses by ultracentrifugation, proteomic and metabolomic techniques. 2) to study the relationship between the hdl subclasses, preβ1 hdl and remnant hdl, and clinical determinants of arteriosclerosis. 3) functional in vitro studies of the hdl subclasses determined in objective 1. 4) to study the role of at determining the low hdl levels. 5) to study the impact of hdl increasing drugs on hdl qualitative changes.

groups of subjects: a) diabetic patients with low hdl; b) non-diabetic patients with low hdl; c) diabetic patients with normal hdl levels; and d) non-diabetic patients with normal hdl levels. the studies will be performed after washing out lipid lowering drugs. intima media thickness (imt) will be performed in all groups. main biochemical techniques will be centralised. isolation and characterisation of hdl subclasses and remnant hdl, as well as a determination and preβ1 hdl will be performed. hdl studies examining hdl proteomic and metabolomic profiles will be performed. functional studies will determine the effects on the endothelium, inflammation, cholesterol efflux and oxidation according the qualitative changes. these hdl measurements will be repeated in group (a), after they are treated with fibrates or niacin. hdl metabolism in adipocytes will be extensively studied, and the clinical associations between hdl alterations and plasma at-derived molecules will be examined.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients * age from 30 years to 70 years * hdl not exceeding 50 mg/dl in men or 60 mg/dl in women exclusion criteria: * to be a smoker * to be diagnosed with diabetes less than three months before * to have triglyceride levels above 400 mg/dl * glycated hemoglobin higher than 9% * albuminuria above 300 mg/mg creatinine * chronic kidney disease (efgr \<30 ml/min/1.73 m2) * advanced retinopathy * neuropathy * cardiovascular disease in the last three months * chronic liver insufficiency * neoplastic disease or any chronic or incapacitating disease

Keywords: hdl niacin fenofibrate diabetes metabolomics
oligosecretary myeloma: prevalence and its clinical significance

Conditions: Multiple Myeloma

Summary: in this study, the investigators aim to investigate the prevalence and clinical course of oligosecretary myeloma.

oligosecretary myeloma is a subgroup of multiple myeloma (mm) characterized by low levels of serum and urine monoclonal (m) protein below thresholds of measurable disease (a serum m protein ≥ 1g/dl, a urine m protein ≥ 200mg/day). patients with oligosecretary myeloma do not have established methods for disease monitoring and clinical informations regarding oligosecretary myeloma are still largely unknown. in this study, we aimed to investigate the prevalence and clinical course of oligosecretary myeloma.

Eligibility criteria:
inclusion criteria: * a subgroup of multiple myeloma (mm) characterized by low levels of serum and urine monoclonal (m) protein below thresholds of measurable disease (a serum m protein ≥ 1g/dl, a urine m protein ≥ 200mg/day) * available clinical data exclusion criteria: * patients without available clinical data

Keywords: oligosecretary multiple myeloma
development and validation of pediatric narcolepsy patient reported outcomes scale

Conditions: Narcolepsy; Obstructive Sleep Apnea

Summary: the purpose of this study is to test a pediatric narcolepsy patient reported outcomes tool to assess pediatric narcolepsy symptoms and their effect on daily functioning and quality of life. the goal is to develop a clinical survey that can improve the care of pediatric narcolepsy.

who is eligible? * children and adolescents with narcolepsy between the ages of 9-17 years * diagnosis must be verified by a signed letter from physician in order to participate * participants must be able to understand the purpose of the study participation details * upon enrollment participants will receive an email containing a link to complete hipaa compliant online surveys about narcolepsy symptoms, quality of life, and daily function. surveys should take no more than 30 minutes. * one week later, some participants will receive another email with a link to complete a 10-minute follow up survey

Eligibility criteria:
inclusion criteria: * children and adolescents ages 9-17 * have a diagnosis of narcolepsy type 1, narcolepsy type 2, or mild to moderate obstructive sleep apnea (osa) exclusion criteria: * a history of visual or hearing impairment * a co-morbid neurodevelopmental disorder such as autism or schizophrenia * no access to computer/tablet/smart phone to complete questionnaires
diagnosis of congenital cytomegalovirus infection in newborn with particular risk

Conditions: Congenital Cytomegalovirus Infection

Summary: congenital cmv infection is the leading cause of non-genetic deafness and neurodevelopmental disorders. its prevalence in france is estimated between 0.3% and 1% of births depending on the study. congenital infection is symptomatic in 10% of cases with a large clinical spectrum with different degree of severity. these sequelae develop progressively and fluctuate, which justifies prolonged follow-up of children for several years, even if they are asymptomatic at birth. there is yet no treatment with amm in neonates or pregnant women. in france, screening for congenital cmv infection is widely debated. it remains oriented to certain newborns considered at risk or depending on their symptoms and varies with the practices of each neonatology or maternity hospital. in the regional maternity of nancy, a new screening protocol for congenital cmv infection was implemented from early 2019. it is based on screening by non-invasive salivary test (cmv pcr) in newborns at particular risk who are included in a registry open for this screening. the aim of this research was to assess the relevance of the proposed criteria in the protocol for defining a population at risk of congenital cmv infection thus qualifying for cmv screening. the secondary endpoints are the modalities of the screening test, the evaluation of each risk factor for infection, and the study of affected patients (symptoms, therapeutic intervention, neurological and auditory outcome).


Eligibility criteria:
inclusion criteria: * newborn born between bebruary 2019 and december 2021 in the regional maternity hospital of nancy * patients who were screened for congenital cmv infection by salivary pcr exclusion criteria: * no one
investigation of wet cupping therapy on heavy metal levels of steel industry workers

Conditions: Heavy Metal Toxicity

Summary: this interventional study investigates the efficacy of wet cupping therapy on heavy metal levels.the levels of the selected heavy metals will be measured in the blood samples obtained from the participants before and after the interventions

wet cupping therapy (wct) is a traditional therapy which was used for centuries especially for detoxifiying purposes.current literature also points out its blood clarifiying capacity in order to illuminate the underlying mechanism of this ancient treatment. steel industry workers, different from the general population are exposed to heavy metals more often.conducting a study in this special group where we will evaluate the levels of selected heavy metals in blood before and after the three sessions of wct might let us know its detoxifiying capacity based on measurable parameters.

Eligibility criteria:
inclusion criteria: * healthy individuals * iron and steel industry workers exclusion criteria: * having any chronic disorder * being on daily medication * wet cupping application in the last 6 months

Keywords: heavy metal wet cupping therapy steel industry worker
transcranial direct current stimulation combined with intermittent oral to esophageal tube on dysphagia

Conditions: Cerebral Infarction

Summary: the study is a double-blind randomized controlled trial, lasting for 15 days for each participant. patients with post-stroke dysphagia who receive treatment at the rehabilitation department are selected as the study subjects. the patients are randomly assigned to either the experimental group or the placebo group. all patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using intermittent oro-esophageal tube. in addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.

transcranial direct current stimulation is currently very popular. the study is a double-blind randomized controlled trial, lasting for 15 days for each participant. patients with post-stroke dysphagia who receive treatment at the rehabilitation department are selected as the study subjects. the patients are randomly assigned to either the experimental group or the placebo group. all patients receive routine rehabilitation therapy and swallowing rehabilitation training, along with enteral nutrition support using intermittent oro-esophageal tube. in addition to these interventions, patients in the experimental group receive transcranial direct current stimulation, while the instruments used for patients in the placebo group only illuminate an indicator light without any actual effect.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for ischemic stroke confirmed by mri or ct; * age \> 18 years; * first-time stroke; * swallowing disorder confirmed by swallowing contrast study or flexible endoscopic evaluation of swallowing; * requires enteral nutrition support; * stable vital signs, no severe cognitive impairment or aphasia, able to cooperate with treatment; * transferred to the rehabilitation department within fifteen days of onset; * stable vital signs. exclusion criteria: * presence of contraindications for invasive oral endoscopy; * concurrent presence of other neurodegenerative diseases that may cause swallowing disorders, such as neurodegenerative diseases; * concurrent presence of other neurological disorders; * tracheostomized patients; * concurrent liver, kidney failure, tumor, or hematological disorders; * pregnancy; * presence of contraindications for transcranial direct current stimulation, such as epilepsy, cerebral edema; * recent use of centrally acting drugs that interfere with the effects of transcranial direct current stimulation, such as carbamazepine, phenytoin, valproic acid, etc.
addressing proven factors in hiv prevention for latino youth

Conditions: HIV; Sexually Transmitted Infections

Summary: this study tests the effectiveness of the bilingual health and success program, which aims to support latino parents and schools in their efforts to promote the academic success and healthy choices of youth, with the goal of reducing barriers that lead to elevated levels of hiv/aids in urban latino communities.


Eligibility criteria:
inclusion criteria: * youth attend school selected as study site * youth in 6-7th grade exclusion criteria: * parent/youth non-english or spanish speakers

Keywords: parenting, prevention, hiv/aids, adolescents, latino
flippin pain: a public health campaign evaluation

Conditions: Pain, Chronic

Summary: an online webinar aiming to improve the public beliefs related to persistent pain will be offered to members of the public in the uk via social media and targeted via written invitation to individuals on a waiting list for pain and musculoskeletal services in ayrshire and arran, scotland.

flippin pain is a uk based public health campaign which aims to shift the populations perception related to persistent pain to one that is aligned with contemporary pain science understanding. the webinar will be presented by a panel consisting of people with a history of persistent pain and healthcare professionals with experience of treating persistent pain. the webinar will be advertised on social media. when registrants receive their confirmation email confirming their place they will be notified of of the invitation to participate. this link within the email will take them to an online participant information sheet. once this is read they may decide to proceed with an online survey which would take 10 minutes to complete. this survey will include some non identifiable demographic data and the pain beliefs questionnaire (pbq). the pbq is a validated tool that does not require a license to use. the survey will be administered immediately after the webinar, at 3, 6 and 12 months to assess for longitudinal changes in pain beliefs. another recruitment strategy will be the posted invitation to individuals on a national health service waiting list. both groups will complete the same survey questions. the last question of the survey will request the participants email so that future surveys can be sent and the follow ups linked by participant. individuals will also be asked within the survey if they consent to further contact about the opportunity to answer questions vie a telephone/online interview related to their experience of the webinar. purposive sampling will be used to recruit 15-20 individuals for a semi structured interview.

Eligibility criteria:
inclusion criteria: * resident within the united kingdom * over the age of 18 years exclusion criteria: * unable to read the english version of the surveys

Keywords: education
survival study for participants treated with ipilimumab-nivolumab combination therapy

Conditions: Melanoma

Summary: this study will review published trial literature and documents for overall survival (os) to evaluate the association between the hazard of death and each baseline variable.


Eligibility criteria:
inclusion criteria: * diagnosis of melanoma exclusion criteria: * age less than 18 years old
effects of aromatherapy on anxiety and pain during dental treatment in adults

Conditions: Dental Anxiety

Summary: dental anxiety is a common problem in dental care. the aim of this protocol is to evaluate the effect of orange and tea essential oil for the control of anxiety and pain in adults during dental treatments.


Eligibility criteria:
inclusion criteria: * patients who need dental treatment, such as resin filling, root canal treatment, periodontal initial treatment, tooth extraction, etc. * be able to understand the purpose of the study and volunteer to take part in the study. * be able to complete all assessments and follow-up during the study. exclusion criteria: * patients who are allergic to the ingredients of the essential oils used in the experiment or to the materials used in the dental treatment. * patients who underwent only an oral examination. * patients with severe heart disease, hypertension, respiratory disease, or other systemic conditions that were not eligible for trial participation. * pregnant or lactating women. * people with depressive symptoms, anxiety disorders or other mental illnesses that affect their mood state. * people who are using sedative or analgesic drugs. * recent or current users of essential oil. * any circumstances considered by the investigator to be inappropriate for participation in this study.
neurological and psychiatric comorbidities patients with fshd 1 and 2

Conditions: Muscular Dystrophy, Facioscapulohumeral

Summary: the investigators propose to conduct a comparative pilot cognitive and psychiatric profiles of 10 patients facio-scapulo-humeral dystrophy (= fhsd) type 1 and 10 patients with type 2 fshd study. for this, the investigators relied on observational components: fshd2 patients appear more often present with psychiatric comorbidities and seem to have lower cognitive performance compared to fshd1 patients. this was confirmed by a preliminary study on a small sample population of patients. it seems to exist mainly executive dysfunction associated with attention disorders in patients fshd2. moreover, their performance in iq tests would be low in relation to their socio-educational and compared with patients fshd1 level.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years and \<75 years * fshd patients 1 or 2 with genetic confirmation exclusion criteria: * phosphokinase creatine level \> 5 time of the normal * patient as medical history : * a history or active neurological disease likely to interfere with the interpretation of results * a history of head trauma * an infectious disease, hormonal, inflammatory or some deficiency may induce cognitive and / or psychiatric troubles * patient with cons-indication for performing a brain mri * pregnant, parturient and lactating (producing a serum pregnancy test)
sildenafil (viagra) for the treatment of dyskinesias in parkinson's disease

Conditions: Parkinson's Disease

Summary: this study is to determine if viagra is effective in reducing dyskinesias in patients with parkinson's disease.

inclusion criteria: 1. diagnosis of idiopathic parkinson's disease. 2. age \> 40 years. 3. willingness and ability to comply with the study requirements and give informed consent.

Eligibility criteria:
inclusion criteria: 1. diagnosis of idiopathic parkinson's disease, hoehn and yahr stage 2.0 to 4.0. 2. presence of drug-induced dyskinesias 3. age\>40 years. 4. willingness and ability to comply with the study requirements and give informed consent. exclusion criteria: 1. atypical parkinsonian syndrome due to drugs, metabolic disorders, encephalitis, or degenerative diseases. 2. history of stereotaxic brain surgery. 3. clinical history of dementia. 4. known major psychiatric disorder, major depression, schizophrenia. known alcoholism or substance dependence within previous 12 months. 5. history of major hematological, renal, or hepatic abnormalities. 6. known coronary artery disease including angina or myocardial infarction within the last 6 months. significant cardiovascular disease including cardiac failure, unstable angina or life-threatening arrhythmia within the last 6 months. 7. history of stroke within the last 6 months. 8. abnormal ekg consistent with cardiac ischemia. 9. treatment with nitrates. nitrates or any no donors in any dosage form (oral, sublingual, transdermal, inhalation, or aerosols). 10. malignant hypertension or sbp . 180 or \<90, or dbp .110 or \<50. 11. history of priapism. 12. known history of retinitis pigmentosa. 13. positive pregnancy test. 14. history of bleeding disorder. 15. patients with active peptic ulcer disease associated with bleeding. 16. unwillingness to use adequate contraceptive methods if of childbearing potential. 17. patients with medical or psychological condition or social circumstances that would impair their ability to participate in the study. 18. use of viagra or any experimental drugs within 30 days of screening visit.

Keywords: parkinson's disease pd dyskinesia treatment motor complications